Original Article

Subject Category: Oligonucleotide Therapy

Molecular Therapy (2009) 17 3, 538–547 doi:10.1038/mt.2008.273

Rational Design Leads to More Potent RNA Interference Against Hepatitis B Virus: Factors Effecting Silencing Efficiency

Kathy Keck1, Esther M Volper2, Ryan M Spengler1, Dang D Long3, Chi Y Chan3, Ye Ding3 and Anton P McCaffrey1

  1. 1Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA
  2. 2Department of Tropical Medicine, Medical Microbiology and Pharmacology, Asia-Pacific Institute of Tropical Medicine and Infectious Diseases, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
  3. 3New York State Department of Health, Wadsworth Center, Albany, New York, USA

Correspondence: Anton P. McCaffrey, Department of Internal Medicine, University of Iowa, MERF 3166, Iowa City, Iowa 52242, USA. E-mail: anton-mccaffrey@uiowa.edu

Received 2 May 2008; Accepted 12 November 2008; Published online 16 December 2008.

Top

Abstract

RNA interference (RNAi) can be an effective antiviral agent; however, overexpression of RNAi can be toxic through competition with the endogenous microRNA (miRNA) machinery. We used rational design to identify highly potent RNAi that is effective at nontoxic doses. A statistical analysis was conducted to pinpoint thermodynamic characteristics correlated with activity. Sequences were selected that conformed to a consensus internal stability profile (ISP) associated with active RNAi, and RNAi triggers were expressed in the context of an endogenous miRNA. These approaches yielded highly active hepatitis B virus (HBV) RNAi. A statistical analysis found a correlation between activity and nucleation by binding within the seed sequence to accessible regions in the target RNA. Guide strands were selected for favorable strand biasing, but increased strand biasing did not correlate with potency, suggesting a threshold effect. Exogenous short hairpin RNAs (shRNAs), but not miRNAs were previously reported to compete with miRNAs for the miRNA/RNAi machinery. In contrast, we show that exogenous Polymerase III- but not Polymerase II-driven miRNAs compete with exogenous miRNAs, at multiple steps in the miRNA pathway. Exogenous miRNAs also compete with endogenous miR-21. Thus, competition with endogenous miRNAs should be monitored even when using miRNA-based therapeutics. However, potent silencing was achieved at doses where competition was not observed.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

RNAi in moderation

Nature Biotechnology News and Views (01 Jul 2006)

RNAi the natural way

Nature Genetics News and Views (01 Nov 2005)

Extra navigation

.
ADVERTISEMENT